Department of Ophthalmology, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2138051. doi: 10.1080/21645515.2022.2138051. Epub 2022 Nov 11.
To report potential vaccine-induced inflammatory ocular adverse events following inactivated COVID-19 vaccination. Retrospective study of patients with uveitis and other ocular complications following inactivated coronavirus disease 2019 (COVID-19) vaccination at a tertiary referral center between May 2021 and August 2021. Data collection consisted of demographic and clinical data. The study included 8 eyes of 5 patients (4 females, 1 male), with a mean age of 37.2 ± 12.5 years (range 28-59 years). Mean time between vaccination and ocular complications onset was 13.2 ± 11.9 days (range 3-30 days), including two patients after the first dose of the vaccine and 3 patients after the second dose. The cases reported were three anterior uveitis, one herpetic keratitis and iridocyclitis, and one posterior uveitis. Patients received treatment with local and/or systemic steroids and all the patients had good visual outcomes. Ocular inflammatory events may occur after vaccination with possible gender preponderance. However, they are rare and manageable. Overall, the efficacy and safety of vaccination should be emphasized.
报告接种灭活 COVID-19 疫苗后潜在的疫苗诱导性炎症性眼部不良事件。对 2021 年 5 月至 2021 年 8 月在一家三级转诊中心接种灭活冠状病毒病 2019 型（COVID-19）疫苗后发生葡萄膜炎和其他眼部并发症的患者进行回顾性研究。数据收集包括人口统计学和临床数据。本研究纳入了 5 名患者（4 名女性，1 名男性）的 8 只眼，平均年龄为 37.2±12.5 岁（范围 28-59 岁）。接种疫苗和眼部并发症发病之间的平均时间为 13.2±11.9 天（范围 3-30 天），包括 2 例患者在接种第一剂疫苗后，3 例患者在接种第二剂疫苗后。报告的病例分别为 3 例前葡萄膜炎、1 例疱疹性角膜炎和虹膜炎、1 例后葡萄膜炎。患者接受了局部和/或全身皮质类固醇治疗，所有患者均有良好的视力结局。接种疫苗后可能会发生眼部炎症性事件，具有性别优势倾向。但是，它们很少见且可管理。总体而言，应强调疫苗的功效和安全性。
